Quercetin pretreated umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease via IL-10 /Janus kinase 2/STAT3 signaling

Figure 2 Quercetin pretreatment enhances human umbilical cord-derived mesenchymal stem cell viability without affecting their immunosuppressive ability. A: Pretreatment of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) with different concentrations of quercetin (QUR) for 24 hours; B: Pretreatment of hUCMSCs with different concentrations of QUR for 48 hours; C-H: QUR can decrease the mRNA expression of interleukin 1 beta (IL-1β), IL-6, colony-stimulating factor-6 (CSF-6), monocyte chemoattractant protein 1 (MCP-1), prostaglandin-endoperoxide synthase 2 (PTGS-2), and tumor necrosis factor-alpha-stimulated gene/protein-6 (TSG-6) in the untreated hUCMSC group. The data are expressed as the mean ± SEM, n = 3. ^aP < 0.05 vs untreated hUCMSC group, ^bP < 0.01 vs untreated hUCMC group.